SAGE 217

Phase 3Small molecule

Biogen

SAGE 217 is one of 38 small molecule programs targeting Postpartum Depression. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Postpartum DepressionActive, not recruiting

Postpartum DepressionPhase 3

Active, not recruiting

Competition

Competitive Landscape

50 competitors in Postpartum Depression

#DrugCompanyPhaseTrials

Zulresso

Biogen

Approved

3 2

Estrace

Novo Nordisk

Approved

1 3

Zoloft

VViatris Specialty LLC

Approved

5 4

Ketalar

AAultman Health Foundation

Approved

2 5

Sufenta

LLeaf Vertical Inc.

Approved

1 6

Ultram

WWim Janssens

Approved

1 7

Prometrium

Ferring

Approved

1 8

Dilaudid

RRhodes Pharmaceuticals, L.P.

Approved

1 9

Naropin

FFresenius Kabi Oncology Ltd.

Approved

1 10

Celebrex

PPhiladelphia Eye Associates

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Postpartum Depression1 trial

A Study to Evaluate SAGE-217 in Participants With Severe Postpartum Depression

Completed· Biogen logo

Biogen·Phase 3·NCT02978326·276 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for SAGE 217. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SAGE 217 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SAGE 217. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Biogen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Biogen

SAGE 217

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Postpartum Depression1 trial

References

Drug Info

Quick Facts

Related News